Cell-free DNA as a prognostic marker in stage I non-small-cell lung cancer patients undergoing stereotactic body radiotherapy

References

• Baumann P, Nyman J, Hoyer M, et al. (2009). Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 27:3290–6
   PubMed Web of Science ®Google Scholar
• Beau-Faller M, Gaub MP, Schneider A, et al. (2003). Plasma DNA microsatellite panel as sensitive and tumor-specific marker in lung cancer patients. Int J Cancer 105:361–70
   PubMed Web of Science ®Google Scholar
• Boyd JA, Hubbs JL, Kim DW, et al. (2010). Timing of local and distant failure in resected lung cancer: implications for reported rates of local failure. J Thorac Oncol 5:211–14
   PubMed Web of Science ®Google Scholar
• Brock J, Ashley S, Bedford J, et al. (2008). Review of hypofractionated small volume radiotherapy for early-stage non-small cell lung cancer. Clin Oncol (R Coll Radiol) 20:666–76
   PubMed Web of Science ®Google Scholar
• Catarino R, Coelho A, Araújo A, et al. (2012). Circulating DNA: diagnostic tool and predictive marker for overall survival of NSCLC patients. PLoS One 7:e38559
   PubMed Web of Science ®Google Scholar
• Chansky K, Sculier JP, Crowley JJ, et al. (2009). International Staging Committee and Participating Institutions. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol 4:792–801
   PubMed Web of Science ®Google Scholar
• Cheng C, Omura-Minamisawa M, Kang Y, et al. (2009). Quantification of circulating cell-free DNA in the plasma of cancer patients during radiation therapy. Cancer Sci 100:303–9
   PubMed Web of Science ®Google Scholar
• DeLong ER, DeLong DM, Clarke-Pearson DL. (1988). Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44:837–45
   PubMed Web of Science ®Google Scholar
• Devonshire AS, Whale AS, Gutteridge A, et al. (2014). Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification. Anal Bioanal Chem 406:6499–512
   PubMed Web of Science ®Google Scholar
• Elshimali YI, Khaddour H, Sarkissyan M, et al. (2013). The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients. Int J Mol Sci 14:18925–58
   PubMed Web of Science ®Google Scholar
• Esposito A, Bardelli A, Criscitiello C, et al. (2014). Monitoring tumor-derived cell-free DNA in patients with solid tumors: Clinical perspectives and research opportunities. Cancer Treat Rev 40:648–55
   PubMed Web of Science ®Google Scholar
• Ferlay J, Shin HR, Bray F, et al. (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–917
   PubMed Web of Science ®Google Scholar
• Fournié GJ, Courtin JP, Laval F, et al. (1995). Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumours. Cancer Lett 91:221–7
   PubMed Web of Science ®Google Scholar
• Gautschi O, Bigosch C, Huegli B, et al. (2004). Circulating deoxyribonucleic acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol 22:4157–64
   PubMed Web of Science ®Google Scholar
• Gormally E, Caboux E, Vineis P, Hainaut P. (2007). Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res 635:105–17
   PubMed Web of Science ®Google Scholar
• Guckenberger M, Allgäuer M, Appold S, et al. (2013). Safety and efficacy of stereotactic body radiotherapy for stage 1 non-small-cell lung cancer in routine clinical practice: a patterns-of-care and outcome analysis. J Thorac Oncol 8:1050–8
   PubMed Web of Science ®Google Scholar
• Hidetaka U, Fumihiro T. (2014). Recurrence after surgery in patients with NSCLC. Transl Lung Cancer Res 3:242–9
   PubMedGoogle Scholar
• Howington JA, Blum MG, Chang AC, et al. (2013). Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143:e278S–313S
   PubMed Web of Science ®Google Scholar
• Kumar S, Guleria R, Mohan A, et al. (2011). Efficacy of plasma TGF-β1 level in predicting therapeutic efficacy and prognosis in patients with advanced non-small cell lung cancer. Cancer Invest 29:202–7
   PubMed Web of Science ®Google Scholar
• Martini N, Bains MS, Burt ME, et al. (1995). Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 109:120–9
   PubMed Web of Science ®Google Scholar
• Paci M, Maramotti S, Bellesia E, et al. (2009). Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer. Lung Cancer 64:92–7
   PubMed Web of Science ®Google Scholar
• Palmer JD, Zaorsky NG, Witek M, Lu B. (2014). Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer. J Thorac Dis 6:387–98
   PubMed Web of Science ®Google Scholar
• Pathak AK, Bhutani M, Kumar S, et al. (2006). Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool. Clin Chem 52:1833–42
   PubMed Web of Science ®Google Scholar
• Ricardi U, Filippi AR, Guarneri A, et al. (2010). Stereotactic body radiation therapy for early stage non-small cell lung cancer: results of a prospective trial. Lung Cancer 68:72–7
   PubMed Web of Science ®Google Scholar
• Ricardi U, Frezza G, Filippi AR, et al. (2014). Stereotactic ablative radiotherapy for stage I histologically proven non-small cell lung cancer: an Italian multicenter observational study. Lung Cancer 84:248–53
   PubMed Web of Science ®Google Scholar
• Sandhu AP, Lau SK, Rahn D, et al. (2014). Stereotactic body radiation therapy in octogenarians with stage I lung cancer. Clin Lung Cancer 15:131–5
   PubMed Web of Science ®Google Scholar
• Senthi S, Lagerwaard FJ, Haasbeek CJ, et al. (2012). Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. Lancet Oncol 13:802–9
   PubMed Web of Science ®Google Scholar
• Sirera R, Bremnes RM, Cabrera A, et al. (2011). Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer. J Thorac Oncol 6:286–90
   PubMed Web of Science ®Google Scholar
• Socinski MA, Morris DE, Masters GA. (2003). American College of Chest Physicians. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest 123:226S–43S
   PubMed Web of Science ®Google Scholar
• Sozzi G, Conte D, Leon M, et al. (2003). Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 21:3902–8
   PubMed Web of Science ®Google Scholar
• Sozzi G, Conte D, Mariani L, et al. (2001). Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res 61:4675–8
   PubMed Web of Science ®Google Scholar
• Sozzi G, Roz L, Conte D, et al. (2009). Plasma DNA quantification in lung cancer computed tomography screening: five-year results of a prospective study. Am J Respir Crit Care Med 179:69–74
   PubMed Web of Science ®Google Scholar
• Suresh KP, Chandrashekara S. (2012). Sample size estimation and power analysis for clinical research studies. J Hum Reprod Sci 5:7–13
   PubMedGoogle Scholar
• Tantraworasin A, Saeteng S, Lertprasertsuke N, et al. (2013). Completely resected n0 non-small cell lung cancer: prognostic factors affecting long-term survival. ISRN Surg 175304
   PubMedGoogle Scholar
• Timmerman R, Paulus R, Galvin J, et al. (2010). Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303:1070–6
   PubMed Web of Science ®Google Scholar
• Trakul N, Chang CN, Harris J, et al. (2012). Tumor volume-adapted dosing in stereotactic ablative radiotherapy of lung tumors. Int J Radiat Oncol Biol Phys 84:231–7
   PubMed Web of Science ®Google Scholar
• van der Drift MA, Hol BE, Klaassen CH, et al. (2010). Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer. Lung Cancer 68:283–7
   PubMed Web of Science ®Google Scholar
• Wang S, Han X, Hu X, et al. (2014). Clinical significance of pretreatment plasma biomarkers in advanced non-small cell lung cancer patients. Clin Chim Acta 430:63–70
   PubMed Web of Science ®Google Scholar
• Yoon KA, Park S, Lee SH, et al. (2009). Comparison of circulating plasma DNA levels between lung cancer patients and healthy controls. J Mol Diagn 11:182–5
   PubMed Web of Science ®Google Scholar
• Zhang R, Shao F, Wu X, Ying K. (2010). Value of quantitative analysis of circulating cell free DNA as a screening tool for lung cancer: a meta-analysis. Lung Cancer 69:225–31
   PubMed Web of Science ®Google Scholar